The aim of this study is to examine the effectiveness of hydroxyurea in treating CML patients in chronic phase. The result of the research shows that the induction treatment with hydroxyurea (initial dose: 40-60mg/kg body weight daily) radically improved clinical condition for CML patients: the size of spleen was reduced in the majority of patients (91.7% and 63.9% patients have palpable spleen (P<0.05), 83.3% and 5.6% patients have enlarged spleen third and forth degree before and after induction treatment respectively, percentage of patients with symptoms of high viscosity syndrome decreased from 36.1% to 0% after treatment with P<0.001, symptoms of anemia were decreased in the majority of patients. The follow up during the time of induction treatment shows that main clinical symptoms (enlarged spleen, high viscosity syndrome, anemia) have improved gradually in accordance with the decrease of WBC
Leukemia ; Hydroxyurea

No abstract available.
Hydroxyurea ; Hyperpigmentation*

No abstract available.
Dermoscopy ; Hydroxyurea

No abstract available.
Hydroxyurea ; Skin ; Skin Ulcer

A retrospective study was carried out in 34 chronic myeloid leukemia patients, who were followed up from the beginning stage of the disease throughout natural history of the disease. The result shows the follows: the percentage of transformation into acute myeloid leukemia was 86.7%, the percentage of transformation into acute lymphocytic leukemia was 13.3%. The median length of chronic phase was 28.9 months. The median survival was 33.6 months (52.4% patients have survived more than 52 months). Main cause of death in chronic phase was emboli due to hyperleucocytic syndrome
Leukemia, Myeloid ; Hydroxyurea ; therapeutics

The aim of this study is to examine the effectiveness of hydroxyurea in treating CML patients in chronic phase. The result of the research shows that the induction treatment with hydroxyurea with initial dose of 40-60mg/kg body weight daily radically improves hematological condition for CML patients in chronic phase. All patients (42 patients) reached hematological remission (33.3% patients reached complete remission), 66.7% patients reached partial remission WBC decrease from 193.9117.7 g/l to 10.16.0 g/l. Percentage of myeloblast, promyelocyte, myelocyte and metamyelocyte in peripheral blood decrease from 35.08.0% to 6.96.6%. Hemoglobin concentration increase from 86.119.0 g/l to 96.013.3 g/l, RBC increase from 2.90.7 T/l to 3.20.5 T/l. The follow up during the time of induction treatment shows that main hematological indicators have changed gradually when approaching normal physiological values
Leukemia ; Hydroxyurea ; therapeutics

A patient with idiopathic hypereosinophilic syndrome is reported who developed a drug fever that may be related to the administration of hydroxyurea. Typically, this form of fever develops after a few weeks of exposure to the drug and disappears with withdrawal of the drug and recurs on reexposure to the drug. The mechanism of hydroxyurea-induced fever remains unclear.
Fever* ; Humans ; Hydroxyurea ; Hypereosinophilic Syndrome

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder of the primitive hematopoietic stem cell. The research is performed to examine the effectiveness of hydroxyurea in treating patients with CML in chronic stage. The results showed that hydroxyurea dramatically improved clinical and hematological condition. All patients reached complete or partial remission
Leukemia ; Hydroxyurea ; therapeutics ; blood ; diagnosis

From January 1997 to January 1998, there were 21 patients with chronic myelogenous leukemia who admitted to the Clinical Department, National Institute of Hematology and Blood Transfusion, B¹ch Mai Hospital. Mean age of patients was 42.85 for men and 38.12 for women. Among these patients, splenomegaly was observed in 100% of patients. Hyperleukocytosis, hyperthrombocytemia, erythrocytopenia, and hyperuricemia all were measured. 94% of patients were positive with Philadelphia chromosome
Leukemia ; Hydroxyurea ; Hematologic Agents ; diagnosis

The association of skin tumors and long-term use of hydroxyurea is recently recognized. We report a case of a patient who developed squamous cell carcinoma on the face during long-term treatment with hydroxyurea for polycythemia vera. As hydroxyurea is frequently used to treat myeloproliferative diseases, we suggest the clinical awareness of the increased risk of skin cancers in patients with long-term hydroxyurea therapy.
Carcinoma, Squamous Cell* ; Humans ; Hydroxyurea* ; Polycythemia Vera ; Skin ; Skin Neoplasms